WO2019122783A1 - Complements alimentaires et leur utilisation sur les menstruations - Google Patents
Complements alimentaires et leur utilisation sur les menstruations Download PDFInfo
- Publication number
- WO2019122783A1 WO2019122783A1 PCT/FR2018/053514 FR2018053514W WO2019122783A1 WO 2019122783 A1 WO2019122783 A1 WO 2019122783A1 FR 2018053514 W FR2018053514 W FR 2018053514W WO 2019122783 A1 WO2019122783 A1 WO 2019122783A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- mass
- daily dose
- composition
- vitamin
- percentage
- Prior art date
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 41
- 210000004914 menses Anatomy 0.000 title abstract description 5
- 239000000203 mixture Substances 0.000 claims abstract description 66
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 64
- 229910052742 iron Inorganic materials 0.000 claims abstract description 32
- 241001092489 Potentilla Species 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 32
- 229930003448 Vitamin K Natural products 0.000 claims description 18
- 241000234314 Zingiber Species 0.000 claims description 18
- 235000006886 Zingiber officinale Nutrition 0.000 claims description 18
- 235000008397 ginger Nutrition 0.000 claims description 18
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 18
- 235000019168 vitamin K Nutrition 0.000 claims description 18
- 239000011712 vitamin K Substances 0.000 claims description 18
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 18
- 229940046010 vitamin k Drugs 0.000 claims description 18
- 229930003427 Vitamin E Natural products 0.000 claims description 16
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 16
- 235000019165 vitamin E Nutrition 0.000 claims description 16
- 239000011709 vitamin E Substances 0.000 claims description 16
- 229940046009 vitamin E Drugs 0.000 claims description 16
- 229940109529 pomegranate extract Drugs 0.000 claims description 15
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 12
- 235000016551 Potentilla erecta Nutrition 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 5
- 241000744472 Cinna Species 0.000 claims description 4
- 240000000103 Potentilla erecta Species 0.000 claims 2
- 229930003270 Vitamin B Natural products 0.000 claims 1
- 235000019156 vitamin B Nutrition 0.000 claims 1
- 239000011720 vitamin B Substances 0.000 claims 1
- 230000005906 menstruation Effects 0.000 description 31
- 208000002193 Pain Diseases 0.000 description 11
- 241000210110 Potentilla argentea Species 0.000 description 11
- 230000036407 pain Effects 0.000 description 11
- 241000219991 Lythraceae Species 0.000 description 8
- 235000014360 Punica granatum Nutrition 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 7
- 235000017803 cinnamon Nutrition 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 208000007106 menorrhagia Diseases 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 150000003180 prostaglandins Chemical class 0.000 description 4
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 4
- 240000000073 Achillea millefolium Species 0.000 description 3
- 235000007754 Achillea millefolium Nutrition 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000001079 digestive effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 206010065347 Premenstrual pain Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 229940087168 alpha tocopherol Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 239000006286 aqueous extract Substances 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 208000022168 hypermenorrhea Diseases 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000186 progesterone Substances 0.000 description 2
- 229960003387 progesterone Drugs 0.000 description 2
- 241000894007 species Species 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000004835 α-tocopherol Nutrition 0.000 description 2
- 239000002076 α-tocopherol Substances 0.000 description 2
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 241000722941 Achillea Species 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 240000008574 Capsicum frutescens Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 244000037364 Cinnamomum aromaticum Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000008857 Ferritin Human genes 0.000 description 1
- 108050000784 Ferritin Proteins 0.000 description 1
- 238000008416 Ferritin Methods 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000036675 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 201000000839 Vitamin K Deficiency Bleeding Diseases 0.000 description 1
- 206010047634 Vitamin K deficiency Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000009875 biological transport Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001841 cholesterols Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 1
- 229940017545 cinnamon bark Drugs 0.000 description 1
- 235000020230 cinnamon extract Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124558 contraceptive agent Drugs 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 229940127234 oral contraceptive Drugs 0.000 description 1
- 239000003539 oral contraceptive agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 208000026773 severe abdominal cramp Diseases 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 208000016794 vitamin K deficiency hemorrhagic disease Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9068—Zingiber, e.g. garden ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1592—Iron
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Definitions
- the present invention relates to the field of food supplements.
- the invention relates to food supplements for their uses in the field of menstruation and associated inconvenience.
- the control of food is restrictive and demanding.
- a carbohydrate increase in particular, glucose causes insulin production causing the activation of Pro-inflammatory prostaglandins involved in the pain and abundance of menstruation.
- a solation envisaged consists in the use of different treatments.
- a first treatment which can be used with drugs which can cause many side and undesirable effects.
- these drugs may also be associated with contraindications.
- Other treatments recommend the use of contraceptives.
- a regular oral contraceptive, hormone-based requires regular dosing, and is unsuitable for alleviating painful and heavy menstruation.
- the invention provides dietary supplements for their uses in the menstrual field.
- the invention relates to a dietary supplement composition
- a dietary supplement composition comprising pofentil and iron.
- the weight percentage of cinquefoil is between 20% and 100%, whereas the weight percentage of iron is between 0.008% and 0.09%.
- the pofenceille helps to maintain a good comfort throughout the menstrual cycle.
- the potentille has anti "inflammatory and pain reduction
- iron contributes to the normal formation of red blood cells and hemoglobin, to the compensation of iron losses due to x menstruation.
- iron helps reduce fatigue and asthenia.
- a daily dose of cinquefoil has a mass of between 0.25 g and 7 g, preferably a daily dose of cinquefoil having a mass of between 4 and 6 g.
- a daily dose of iron has a mass of between 1 g and 14 g, preferably a daily dose of iron has a mass of between 2 mg and 7 mg.
- the composition comprises ginger in a mass percentage of between 3% and 25%.
- a daily dose of ginger has a mass of between 0.25 g and 4 g, preferably a daily dose of ginger has a mass of between 1 g and 2 g.
- a fourth characteristic of the invention comprising vitamin E or vitamin K in a percentage of less than 0.1%.
- composition may comprise vitamin E in a mass percentage of between 0.008% and 0.06%, preferably a daily dose of vitamin E has a mass of 1 g and 15 g.
- composition may also comprise vitamin K in a mass percentage of between 0.0001% and 0.0005%, preferably a daily vitamin K dosage has a mass is between 10 ⁇ g and 75 ⁇ g.
- the composition may comprise the illetrape in a weight percentage of between 15% and 70%.
- a daily dose of yarrow has a mass of between 0.15 g and 15 g.
- a daily dose of the einnamone extract present does not include 0.5 g and 2 g.
- the composition may comprise a pomegranate extract according to a mass percentage of between 1% and 45%, and preferably the pomegranate extract has a mass percentage of between 20% and 25%, the invention, a daily dose of pomegranate extract has a mass of between 1 g and 4 g, and preferably an oral dose of the pomegranate extract has a size of between 1.5 g and 2.5 g,
- 1 / invention further relates to a metho e limitation of abundant menstruation comprising the regular administration, preferably daily, a composition according to the invention.
- the administration is made over a period ranging from one to several days, more preferably 3 days, before the onset of menstruation, to one to several days, more preferably 2 days after the beginning of mentruations.
- the present invention relates to the field of food supplements. More particularly, the invention relates to dietary supplements for their uses in the field of menstruation.
- the invention finds a particular, non-limiting application in the art . respectively attenuation of painful and abundant menstruation.
- the composition of food supplements according to the invention comprises potentilla.
- Potentilla is a perennial plant of arctic and temperate regions, belonging to the genus Potentilla and Rosaceae family.
- a preferred species for the composition according to the invention is Potenfcilla itHserina-
- the aerial part of potentilla is used. preferably for the production of the composition of food supplements according to the invention.
- an extract of aerial parts concentrated to 4/1 is used.
- the food supplement composition according to the invention comprises a mass percentage of potentilla of between 20% and 55%, preferably, the mass percentage of cinquefoil between 25% and 35%,
- these mass percentages correspond for a daily dose to a potentilla mass of between 0.25 g and 7 g.
- the potentilla mass of a daily dose is between 4 g and 6 g.
- a daily dose corresponds to the quantity to be administered per day.
- the mass of cinquefoil is preferably between 4 g and 6 g. These ranges allow to benefit sufficiently from the effects of cinquefoil. Preferably, this mass is less than 7 g. Indeed, beyond 7 g per daily dose, it is recognized that potentilla is likely to cause digestive disorders.
- the composition of food supplements according to the invention comprises iron.
- Iron is one of the trace elements essential to the body. Iron is an essential constituent of hemoglobin and myoglobin, as well as several enzymes and cytochromes. Iron is also present in the circulation, bound to transferrin, and as a ferritin reserve, mainly in the liver. During menstruation iron losses are increased which can even lead to deficiencies.
- the dietary supplement composition according to the invention may comprise iron according to a mass percentage of between 0.008% and 0.08%.
- the iron has a weight percentage of between 0.02% and 0.006%.
- these mass percentages correspond to a daily dose at an iron mass of between 1 g and 15 mg, preferably the mass of iron is between 2 mg and 7 mg. This is particularly the mass of a daily dose,
- iron may be used as ferric-Sodium-EBT ⁇ complex, this complex type is commercially available for example under the name Ferrasoae ®, the complex allows to make the bio-available iron.
- composition of food supplements according to the invention comprises at least one additional component in excipient form.
- the excipient allows the stability of the composition, facilitates its biological transport, influences the palatability and allows a mode of administration and a specific galenic.
- the composition of additive supplements is in the form of tablets.
- composition of food supplements may comprise, according to one embodiment of the invention, ginger.
- Ginger is a plant native to Asia with an aromatic rhizome belonging to the family Eingihéraceae.
- One preferred species for the composition of dietary supplements adapted to alleviate menses abundant according to the invention is fingifcer Offal® Roscc-e,
- the root portion of ginger is used preferentially for the realization of the composition.
- Ginger contributes to physical well-being.
- ginger comprises anti-inflammatory agents and has an inhibitory effect on prostaglandin synthesis which makes it possible to reduce hyper-enorrhea.
- hypermenorrhea is linked to an increase in prostaglandin concentration.
- composition of food supplements can comprise a mass percentage of ginger of between 3% and 2%.
- weight percentage of ginger is between 9% and 15%,
- these mass percentages correspond for a daily dose of ginger a mass of between 0.25 g and 4 g.
- the mass of ginger is between 1 g and 2 g. This mass is an equivalent in ginger, and in particular rhizome of ginger.
- composition of food supplements according to the invention may also comprise vitamins.
- the composition of food supplements may comprise vitamin K in a percentage by weight of less than 0.1%.
- Vitamin K is a vitamin derived from quinones. It is an enzymatic cofactor that is also involved in the maturation of certain coagulation factors. Thus , vitamin K helps to generate normal blood clotting. Oc, it has been shown that vitamin K deficiency can lead to hemorrhages that increase blood flow during menstruation and excessive menstruation,
- composition of nutritional supplements comprising vitamin K is more particularly intended to ameliorate heavy menstruation.
- vitamin K ensures normal blood coagulation which limits blood loss during men truations.
- vitamin K is associated with potentilia and iron, the beneficial effects of this compound work together to reduce the discomfort of heavy menstruation.
- the composition may comprise vitamin K in a mass percentage of between 0.0001% and 0.0005%.
- the vitamin K present a weight percentage between 0.00025% and 0.00035,
- these mass percentages correspond for a daily dose to a vitamin K mass of between 10 ⁇ g and 7 ⁇ g.
- the mass of vitamin K is between 12 ⁇ g and 35 ⁇ g. Such a mass gives good results.
- a daily intake greater than 75 pg goes beyond the recommended intakes ⁇
- the food supplement composition may also include a pomegranate extract.
- the pomegranate Fumica granatu is a fruit of the family Punicaeeaa which is derived from pomegranate. In this.
- a pomegranate extract from dried pomegranate flowers is used.
- the pomegranate contains flavancls, ellagitannins, flavonoids, and anthocyanosides. These chemical compounds provide the pomegranate with hypotensive and anti-inflammatory effects. cholesterols.
- pomegranate helps reduce the duration of bleeding reducing joint monthly losses, so the pomegranate can increase the concentration of hemoglobin following a menstrual cycle.
- a pomegranate extract may be introduced together with vitamin K to form a dietary supplement composition that is intended to ameliorate heavy menstruation. Indeed, reducing the duration of bleeding helps to relieve a phenomenon of heavy menstruation.
- composition of food supplements can comprise a pomegranate extract in a weight percentage of between 15% to 45%.
- the weight percentage of pomegranate extract is between 20% and 25%.
- the food supplement composition may comprise a cinnamon extract more commonly known as name of cinnamon.
- the cinnamon Cinnamoniis eassia of the family Lauraceae comes from a tree called the Cannai1er of China.
- an aqueous extract of Chinese cinnamon bark was used . This aqueous extract has a ratio of 4: 1.
- Cinnamon contains compounds of the proanfchocyanidin and cinnamaldehyde type which are especially recognized for their antioxidant property. According to cinna one is also known for its antibacterial virtues, painkillers etc. In addition, a study has recently shown that Cinnamon reduces blood loss, digestive disorders (pain, nausea, vomiting) as well as pain during the period of menstruation. In view of these beneficial effects on heavy menstruation, a cinna one extract can be added to a dietary supplement composition that seeks to alleviate heavy menstruation. Indeed, the reduction of blood loss, digestive disorders and pain participates together with the effects of other components of this composition to reduce a phenomenon of heavy menstruation.
- composition of dietary supplements may comprise an entry of cinaaraone in a mass percentage of between 10% and 25%.
- cinnamone extract has a weight percentage of between 12% and 17%.
- these mass percentages correspond to a daily dose of between 0.5 g and 2 g of cmnamené extract.
- the cinnamone extract mass of a daily dose is between 1 g and 1.5 g. Such a mass gives significant results, whereas a daily intake greater than 2 g goes beyond the recommended intakes,
- Vitamin E is a fat-soluble vitamin derived from the chro anol nucleus. It is an antioxidant reducing oxidative stress. It avoids the excessive aggregation of platelets responsible for thromboses, and. has a protective action on red blood cells,
- Vitamin E interacts with other vitamins and hormones including progesterone which has a relaxing effect on the uterine muscles and decreases the risk of bleeding.
- vitamin E modulates inflammatory processes through its action on prostaglandins involved in uterine contractions and therefore pain.
- Vitamin E helps to reduce premenstrual and menstrual pain.
- the addition of Vitamin E to a composition of food supplements makes it particularly possible to reduce menstrual pain.
- the reduction of pains and menstrual pains which is favored by vitamin E contributes in collaboration with the effects of iron and pofcentille to alleviate pain associated with painful menstruation.
- vitamin E may be in the form of alpha tocopherol and more particularly alpha fcocopherol succinate.
- the succinate makes it possible to increase the conservation of alpha tocopherol as well as its absorption.
- composition of dietary supplements comprises vitamin E in a percentage by weight of between 0.008% and 0.06%.
- vitamin E has a weight percentage of between 0.01% and 0.03%.
- these mass percentages correspond to a vitamin E mass of between 1 mg and 12 g.
- the mass of a daily dose is between 2 mg and 6 mg. Such a mass gives significant results. Conversely, a mass per dose greater than 12 mg would go beyond the recommended daily intakes.
- composition of food supplements may also include an achiliate
- the achiliate is a creeping root plant belonging to the family of asfceraceae. According to the invention it is preferable to use X'Achillea Millefolitm. or achillee illefeuilie. As an indication, the tops or upper parts of the achille millefeuilie may be used in powder form within the scope of the invention.
- Chillie millefeuilie thanks to its antispasmodic and anti-inflammatory properties, helps to soothe abdominal cramps by interacting for example with progesterone. Consequently, the chiliea millefeuilie allows the reduction of premenstrual and menstrual pains. In this sense, he is. It is possible to incorporate the achille miilefeuille into a composition of dietary supplements to treat painful menstruation.
- composition of dietary supplements can comprise a minimum amount of 15% to 70% by weight.
- percentage of yarrow is between 35% and 55%.
- these mass percentages correspond for a daily dose to a yarrow mass of between 0.15 g and 15 g.
- the mass of chilli and illefeuille of a daily dose is between 5 g and 13 g. These mass ranges give good results on the reduction of the discomfort associated with painful menstruation.
- the invention further relates to the use of the compositions described above in particular in f attenuation painful menstruation is the limitation of heavy menstruation.
- the above compounds are administered below the recommended daily doses, in particular less than 14 g of active iron per day, less than 7 g of potentilla per day.
- Examples 1 to 5 correspond to embodiments, in accordance with the invention, of a composition of food supplements for reducing painful menstruation.
- Table 3 below is a composition of dietary supplements adapted to ameliorate heavy menstruation. The dose is administered in tablet form.
- composition of Example 5 is 11 poux- alleviate heavy periods, it has neither d r einna ⁇ one extract and pomegranate extract or dl.
- Microcrystalline cellulose 102, BC 95® heavy carbonate calcium, Trieafos 200-7 and carboxymethylcellulose are commercially available agents for the manufacture of tablets,
- Regular administration preferably daily for example, in the form of tablets of the dietary supplement composition adapted to ameliorate heavy menstruation helps to limit heavy menstruation.
- the dosage is more than 3 and preferably less than 5 units per day.
- a dosage of 4 units per day allows to stay within the nutritional values recommended for the majority of the elements of the composition (see table 3, actual active column per day).
- Each unit has a weight without filming 9S0 m.
- the tablets have a longitudinal shape to facilitate ingestion, it can be a cylindrical shape with rounded bases,
- the administration can be done over a period of 5 consecutive days ranging from 3 days before 5 menses and 2 days after the start of the treatments. It is possible to envisage a variant in which the administration begins at the appearance of the signs, and / or ends at the end of the signs.
- Examples 6 to 10 illustrated in Tables 4 to 6 below correspond to embodiments, in accordance with the invention, of a composition of food supplements for reducing heavy menstruation.
- Example 10 is a composition of food supplements adapted to alleviate painful menstruation. The dose is administered in the form of tablets.
- the dietary supplement composition of Example 10 is adapted to alleviate painful menstruation.
- the dosage is similar to the dosage of Example 5, for example, for example, in a dose of four units per day. Each unit has a weight of 950 g without pailieulaga.
- the administration can be made over a period of 5 consecutive days ranging from 3 days before menstruation and 2 days after the beginning of menstruation.
- a variant may be considered in which administration begins at the onset of symptoms, and / or terminates at the end of symptoms.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gynecology & Obstetrics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18842712.4A EP3727417A1 (fr) | 2017-12-21 | 2018-12-21 | Complements alimentaires et leur utilisation sur les menstruations |
CN201880081525.9A CN111542331A (zh) | 2017-12-21 | 2018-12-21 | 膳食补充剂及其在月经中的用途 |
BR112020012592-0A BR112020012592A2 (pt) | 2017-12-21 | 2018-12-21 | suplementos alimentares e uso dos mesmos para menstruações |
AU2018390108A AU2018390108A1 (en) | 2017-12-21 | 2018-12-21 | Dietary supplements and use thereof on menses |
KR1020207018903A KR20200102452A (ko) | 2017-12-21 | 2018-12-21 | 식이 보조제 및 생리에 대한 이의 사용 |
US16/956,312 US20200323940A1 (en) | 2017-12-21 | 2018-12-21 | Dietary supplements and use thereof on menses |
CA3086386A CA3086386A1 (fr) | 2017-12-21 | 2018-12-21 | Complements alimentaires et leur utilisation sur les menstruations |
JP2020554945A JP2021508258A (ja) | 2017-12-21 | 2018-12-21 | 月経に対する栄養補助食品およびそれらの使用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1762870A FR3075601A1 (fr) | 2017-12-21 | 2017-12-21 | Complements alimentaires et leur utilisation sur les menstruations |
FR1762870 | 2017-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019122783A1 true WO2019122783A1 (fr) | 2019-06-27 |
Family
ID=62222765
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR2018/053514 WO2019122783A1 (fr) | 2017-12-21 | 2018-12-21 | Complements alimentaires et leur utilisation sur les menstruations |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200323940A1 (fr) |
EP (1) | EP3727417A1 (fr) |
JP (1) | JP2021508258A (fr) |
KR (1) | KR20200102452A (fr) |
CN (1) | CN111542331A (fr) |
AU (1) | AU2018390108A1 (fr) |
BR (1) | BR112020012592A2 (fr) |
CA (1) | CA3086386A1 (fr) |
FR (2) | FR3075601A1 (fr) |
MA (1) | MA51321A (fr) |
WO (1) | WO2019122783A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20240054648A (ko) | 2022-10-19 | 2024-04-26 | 대구한의대학교산학협력단 | 궐마 추출물을 포함하는 대사성 질환의 예방 또는 치료용 약학적 조성물 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042153A1 (fr) * | 2005-10-11 | 2007-04-19 | Bayer Consumer Care Ag | Mélange de sels de fer et de cuivre masquant un goût métallique |
EP2682123A2 (fr) * | 2011-03-03 | 2014-01-08 | Obshestvo S Ogranichennoj Otvetstvennostju "PARAFARM" | Additif bioactif destiné à la normalisation de la fonction de la glande thyroïde |
CN103536877A (zh) * | 2013-10-18 | 2014-01-29 | 潘曙东 | 一种治疗痛经的中药组合物 |
EP2705761A1 (fr) * | 2012-09-10 | 2014-03-12 | Laboratoires France Bebe Nutrition | Composition nutritionnelle pour femme enceinte |
CN103893415A (zh) * | 2014-04-24 | 2014-07-02 | 徐静 | 一种治疗月经不调的药物及制备方法 |
CN105582518A (zh) * | 2016-03-01 | 2016-05-18 | 许崇兰 | 一种治疗痛经的中药制剂及制备方法 |
WO2016141124A1 (fr) * | 2015-03-04 | 2016-09-09 | Keryx Biopharmaceuticals, Inc. | Utilisation de citrate ferrique dans le traitement de l'anémie sidéropénique |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2148659A2 (fr) * | 2007-04-13 | 2010-02-03 | Somaxon Pharmaceuticals, Inc. | Formulations de doxépine à faible dose et procédé de préparation et d'utilisation de celle-ci |
-
2017
- 2017-12-21 FR FR1762870A patent/FR3075601A1/fr active Pending
-
2018
- 2018-12-21 FR FR1873779A patent/FR3076208A1/fr active Pending
- 2018-12-21 CN CN201880081525.9A patent/CN111542331A/zh active Pending
- 2018-12-21 BR BR112020012592-0A patent/BR112020012592A2/pt not_active Application Discontinuation
- 2018-12-21 CA CA3086386A patent/CA3086386A1/fr active Pending
- 2018-12-21 AU AU2018390108A patent/AU2018390108A1/en not_active Abandoned
- 2018-12-21 JP JP2020554945A patent/JP2021508258A/ja active Pending
- 2018-12-21 KR KR1020207018903A patent/KR20200102452A/ko unknown
- 2018-12-21 EP EP18842712.4A patent/EP3727417A1/fr not_active Ceased
- 2018-12-21 MA MA051321A patent/MA51321A/fr unknown
- 2018-12-21 US US16/956,312 patent/US20200323940A1/en not_active Abandoned
- 2018-12-21 WO PCT/FR2018/053514 patent/WO2019122783A1/fr unknown
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007042153A1 (fr) * | 2005-10-11 | 2007-04-19 | Bayer Consumer Care Ag | Mélange de sels de fer et de cuivre masquant un goût métallique |
EP2682123A2 (fr) * | 2011-03-03 | 2014-01-08 | Obshestvo S Ogranichennoj Otvetstvennostju "PARAFARM" | Additif bioactif destiné à la normalisation de la fonction de la glande thyroïde |
EP2705761A1 (fr) * | 2012-09-10 | 2014-03-12 | Laboratoires France Bebe Nutrition | Composition nutritionnelle pour femme enceinte |
CN103536877A (zh) * | 2013-10-18 | 2014-01-29 | 潘曙东 | 一种治疗痛经的中药组合物 |
CN103893415A (zh) * | 2014-04-24 | 2014-07-02 | 徐静 | 一种治疗月经不调的药物及制备方法 |
WO2016141124A1 (fr) * | 2015-03-04 | 2016-09-09 | Keryx Biopharmaceuticals, Inc. | Utilisation de citrate ferrique dans le traitement de l'anémie sidéropénique |
CN105582518A (zh) * | 2016-03-01 | 2016-05-18 | 许崇兰 | 一种治疗痛经的中药制剂及制备方法 |
Non-Patent Citations (4)
Title |
---|
DAILY JAMES W ET AL: "Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials.", PAIN MEDICINE (MALDEN, MASS.) 12 2015, vol. 16, no. 12, 2015, pages 2243 - 2255, XP055509701, ISSN: 1526-4637 * |
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; 1949, YOUNGKEN JR H ET AL: "The muscle relaxant effects produced by Potentilla anserina extracts. I. Fractionation studies", XP055509787, Database accession no. EMB-0008850122 * |
DATABASE WPI Week 201655, Derwent World Patents Index; AN 2016-33567H, XP055509847 * |
MOHAMMADHOSSEINI MAJID ET AL: "Chemical composition of the essential oils and extracts ofAchilleaspecies and their biological activities: A review", JOURNAL OF ETHNOPHARMACOLOGY, vol. 199, 2017, pages 257 - 315, XP029940021, ISSN: 0378-8741, DOI: 10.1016/J.JEP.2017.02.010 * |
Also Published As
Publication number | Publication date |
---|---|
BR112020012592A2 (pt) | 2020-11-24 |
FR3075601A1 (fr) | 2019-06-28 |
MA51321A (fr) | 2021-03-31 |
JP2021508258A (ja) | 2021-03-04 |
KR20200102452A (ko) | 2020-08-31 |
AU2018390108A1 (en) | 2020-07-09 |
FR3076208A1 (fr) | 2019-07-05 |
CA3086386A1 (fr) | 2019-06-27 |
US20200323940A1 (en) | 2020-10-15 |
EP3727417A1 (fr) | 2020-10-28 |
CN111542331A (zh) | 2020-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2459013B1 (fr) | Composition nutritive pour femmes allaitant | |
US20080003278A1 (en) | Food products and dietary supplements for improving mental performance | |
FR2815227A1 (fr) | Composition anti-stress destinee a etre incorporee principalement a des vehicules nutritionnels | |
CN105054025A (zh) | 一种用于炎症性肠病患者的低脂低渗低渣型肠内营养粉剂 | |
WO2019240943A1 (fr) | Composition nutritionnelle à base de protéine de pois intacte | |
KR102262306B1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
US20040001862A1 (en) | Compositions and methods for body weight loss | |
EP1827139A2 (fr) | Composition alimentaire supplementaire afin de favoriser la perte de poids | |
US7674484B2 (en) | Dietary supplement including He Shou Wu, parasitic loranthus and green tea to promote weight loss | |
US10426749B2 (en) | Safflower oil emulsion as dietary supplement and preparation thereof | |
CN103651949A (zh) | 一种养生减肥型调和油 | |
US20020155182A1 (en) | Chia seed beverage and method | |
EP1536697B1 (fr) | Composition comprenant en association au moins une huile de courge et au moins une huile de bourrache, son utilisation comme medicament, comme agent dermatologique ou dermato-cosmetique | |
WO2019122783A1 (fr) | Complements alimentaires et leur utilisation sur les menstruations | |
US20050069593A1 (en) | Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid | |
Balasubramanian et al. | Peanut as a smart food and their nutrients aspects in planet: a review | |
KR101992174B1 (ko) | 복합 한방약초를 포함하는 숙취 예방, 숙취 해소 및 간 보호용 정제형 조성물 및 그 제조방법 | |
CN105851352A (zh) | 一种含白茶提取物的有效部位组合物及其制备方法和应用 | |
KR20030087762A (ko) | 여성의 활력 증진을 위한 건강보조식품 및 그 조성물 | |
CN103494194B (zh) | 一种雄蜂参七胶囊及生产工艺 | |
Hamdia et al. | Effect of some Herbs in Improvement of Anemia in Rats | |
JPS63133969A (ja) | 栄養補助食品 | |
WO2024124239A2 (fr) | Complément alimentaire et méthodes d'utilisation associées | |
KR20040034326A (ko) | 산삼 배양근 추출물을 함유한 건강식품 및 그 제조방법 | |
RU2616399C1 (ru) | Способ получения биологически активного продукта для адаптивного питания и биологически активный продукт для адаптивного питания |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18842712 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3086386 Country of ref document: CA Ref document number: 2020554945 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018390108 Country of ref document: AU Date of ref document: 20181221 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2018842712 Country of ref document: EP Effective date: 20200721 |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112020012592 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112020012592 Country of ref document: BR Kind code of ref document: A2 Effective date: 20200619 |